Table 1.
Agonist Potencies and Efficacies in cAMP, pERK, Internalization, β-Arrestin-1 and −2 Pathways (pEC50 and EMAX ± SEM), n (Independent Determinations) = 3–5
| CP55,940 | AMB-FUBINACA | WIN55,212–2 | Δ9-THC | ||
|---|---|---|---|---|---|
| cAMP (n = 4) | pEC50 | 9.20 ± 0.10 | 9.18 ± 0.18 | 8.12 ± 0.14 | 7.78 ± 0.26 |
| Emax (span, %) | 99.4 ± 3.8 | 101.1 ± 5.8 | 92.1 ± 3.3 | 67.8 ± 8.8 | |
| pERK (n = 4, WIN n = 3) | pEC50 | 8.35 ± 0.18 | 8.80 ± 0.16 | 6.91 ± 0.11 | 7.23 ± 0.03 |
| Emax (span, %) | 100 ± 1.1 | 118.2 ± 3.9 | 113.8 ± 1.5 | 50.9 ± 5.9 | |
| internalization (n = 3) | pEC50 | 8.28 ± 0.13 | 8.14 ± 0.03 | 6.60 ± 0.17 | 7.14 ± 0.12 |
| Emax (1/MRT) | 0.0753 ± 0.0040 | 0.1197 ± 0.0082 | 0.1465 ± 0.0081 | 0.023 ± 0.0035 | |
| β-arrestin-1 (n = 4) | pEC50 | 7.29 ± 0.33 | 7.05 ± 0.09 | ~5.48 ± 0.17 | ND |
| Emax (span, %) | 19.1 ± 9.6 | 101.7 ± 2.5 | ND | ND | |
| β-arrestin-2 (n = 4) | pEC50 | 6.75 ± 0.14 | 7.26 ± 0.04 | ~5.89 ± 0.05 | ND |
| Emax (span, %) | 57.2 ± 2.6 | 102.4 ± 1.3 | ND | ND |